ALung is now proud to be part of LivaNova.

ALung believes peer-reviewed literature is an important part of educating the clinical community about new technologies such ECCO2R. The following table of publications is intended as an educational tool to aid in clinician understanding of ECCO2R and HEMOLUNG therapy.

The HEMOLUNG must be used in accordance with the approved indication for use.

Indication for Use: The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.

Select HEMOLUNG Publications

Avoid Intubation

De-Escalate Mechanical Ventilation Settings

Correct Hypercapnia and Respiratory Acidosis


Summary of HEMOLUNG® Publications 2022